Shyamprasad Deraje Vasudeva

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

Gary K. Schwartz, William D. Tap, Li-Xuan Qin et al. · The Lancet Oncology · 2013 · 186 citations · Full text

MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma

Emily K. Slotkin, Parag P. Patwardhan, Shyamprasad Deraje Vasudeva et al. · Molecular Cancer Therapeutics · 2014 · 94 citations · Full text

Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype

Alan L. Ho, Elgilda Musi, Grazia Ambrosini et al. · PLoS ONE · 2012 · 76 citations · Full text

Mtor Kinase Inhibition, Cell Death, Dermatology +17

PDGF Receptor Alpha Is an Alternative Mediator of Rapamycin-Induced Akt Activation: Implications for Combination Targeted Therapy of Synovial Sarcoma

Alan L. Ho, Shyamprasad Deraje Vasudeva, Marick Laé et al. · Cancer Research · 2012 · 66 citations

Combination Targeted Therapy, Synovial Sarcoma, Medicine +13

Alliance A091104: A phase II trial of MK-2206 in patients (pts) with progressive, recurrent/metastatic adenoid cystic carcinoma.

Alan L. Ho, Nathan R. Foster, Jeffrey P. Meyers et al. · Journal of Clinical Oncology · 2015 · 13 citations

Tumor Biology, Incurable Acc, Phase Ii Trial +14